Gene Therapy Clinical Trial Design Best Practices for 2026

Designing clinical trials for gene therapies presents unique challenges compared to conventional drug development. The one-time or long-acting nature of many gene therapies, the small patient populations for rare disease indications, the novelty of the safety profile, and the intensity of regulatory scrutiny all require specialized approaches to study design, endpoint selection, and data management. The following best practices reflect current regulatory expectations and scientific consensus entering 2026.

Regulatory Strategy and Early Agency Engagement

Early and consistent engagement with regulatory agencies — the FDA's Center for Biologics Evaluation and Research (CBER), the EMA's Committee for Advanced Therapies (CAT), and their international counterparts — is essential for gene therapy developers. Agency guidance documents specifically addressing gene therapy, including FDA's 2024 updated guidelines on long-term follow-up and the EMA's guidelines on quality, non-clinical, and clinical aspects of gene therapy medicinal products, should be reviewed thoroughly before IND or CTA submission. Pre-IND and scientific advice meetings allow developers to align on acceptable endpoints, manufacturing standards, and safety monitoring requirements before committing to expensive late-stage studies. Breakthrough therapy, fast track, and priority medicines (PRIME) designations are available for therapies addressing serious conditions with significant unmet need and can substantially accelerate development timelines.

Endpoint Selection for Rare Disease Populations

Many gene therapy indications involve rare diseases where large randomized controlled trials are impractical. Regulators have increasingly accepted surrogate and intermediate endpoints that are reasonably likely to predict clinical benefit, as well as natural history data as external controls in place of randomized placebo arms. Selecting the right primary endpoint requires deep understanding of the disease's natural history, the mechanism of action of the therapy, and which clinical outcomes are most meaningful to patients and caregivers. Patient advocacy groups are valuable partners in this process, and their input on clinically meaningful change thresholds carries weight in regulatory discussions. Biomarkers validated to correlate with clinical outcome can serve as primary endpoints in accelerated approval pathways with confirmatory trials required post-approval.

Long-Term Follow-Up and Safety Monitoring

FDA guidance requires long-term follow-up (LTFU) of gene therapy participants for up to fifteen years after administration, given the theoretical risks of insertional mutagenesis, delayed immune reactions, and germline transmission. LTFU protocols must be designed into the study from the beginning — not retrofitted after approval — and should specify the frequency and nature of safety assessments, the data collection infrastructure required, and strategies for maintaining participant engagement over a decade or more. Building registries that can integrate LTFU data from multiple trials and cohorts facilitates pooled safety analysis and supports post-market surveillance commitments made to regulators at the time of approval.

Manufacturing Comparability and Quality Considerations

Changes to the manufacturing process between clinical phases — inevitable as production scales from Phase I to commercial quantities — must be carefully managed to demonstrate product comparability. Regulators expect developers to characterize their products extensively and to provide head-to-head analytical and, where necessary, clinical bridging data when significant process changes occur. Establishing a robust analytical control strategy early, including assays for vector genome titer, full-to-empty ratio, infectious titer, residual impurities, and potency, is critical both for regulatory submissions and for ensuring consistent therapeutic performance across batches.

GeneConversions supports gene therapy programs across the full development lifecycle. Learn more on our homepage or contact us to discuss your clinical development strategy.